지구성 운동이 MPTP로 유도된 파킨슨 질환 모델 쥐의 선조체에서 α-synuclein과 miRNA의 발현에 미치는 영향

키워드

참고문헌 (59)

1. Blesa J, "Classic and new animal models of parkinson’s disease", Journal of Biomedicine and Biotechnology, 2012, pp.845618~ (2012)
2. Goetz CG, "The history of Parkinson’s disease: Early clinical descriptions and neurological therapies", Cold Spring Harbor Perspectives in Medicine, 1(1), pp.a008862~ (2011)
3. Willis AW, "Parkinson disease in the elderly adult", Missouri Medicine, 110(5), pp.406~410 (2013)
4. WHO, "Neurological disorders: public health challenges" (2006)
5. National Health Insurance Service, "2014 Major statistics of health insurance for the first half year", ~ (2014)
6. Braak H, "Staging of brain pathology related to sporadic Parkinson’s disease", Neurobiology of Aging, 24(2), pp.197~211 (2003)
7. Fahn, S., "Description of Parkinson’s disease as a clinical syndrome", Annals of the New York Academy of Sciences, 991(1), pp.1~14 (2003)
8. Heyer MP, "Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice", The Journal of Neuroscience, 32(32), pp.10887~10894 (2012)
9. Hong S, "Dopamine system : manager of neural pathways", Frontiers in Human Neuroscience, 7, pp.854~ (2013)
10. Spillantini MG, "Alpha-synuclein in Lewy bodies", Nature, 388(6645), pp.839~840 (1997)
11. Eriksen JL, "Caught in the act : alpha-synuclein is the culprit in Parkinson’s disease", Neuron, 40(3), pp.453~456 (2003)
12. Uversky VN, "A protein-chameleon : Conformational plasticity of alphasynuclein, a disordered protein involved in neurodegenerative disorders", Journal of Biomolecular Structure & Dynamics, 21(2), pp.211~234 (2003)
13. McCann H, "α-Synucleinopathy phenotypes", Parkinsonism & Related Disorders, 20(1), pp.S62~S67 (2014)
14. Feany MB, "A Drosophila model of Parkinson’s disease", Nature, 404(6776), pp.394~398 (2000)
15. Doxakis E, "Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153", The Journal of Biological Chemistry, 285(17), pp.12726~12734 (2009)
16. Junn E, "Repression of α-synuclein expression and toxicity by microRNA-7", Proceedings of the National Academy of Sciences, 106(31), pp.13052~13057 (2009)
17. Bilen J, "A new role for microRNA pathways : Modulation of degeneration induced by pathogenic human disease proteins", Cell Cycle, 5(24), pp.2835~2838 (2006)
18. Harraz MM, "MicroRNAs in Parkinson’s disease", Journal of Chemical Neuroanatomy, 42(2), pp.127~130 (2011)
19. Saugstad JA., "MicroRNAs as effectors of brain function", Stroke, 44(6 Suppl 1), pp.S17~S19 (2013)
20. Morris KV, "RNA-mediated transcriptional gene silencing in human cells", Current Topics in Microbiology and Immunology, 320, pp.211~224 (2008)
21. Rana TM, "Illuminating the silence : Understanding the structure and function of small RNAs", Nature Reviews Molecular Cell Biology, 8(1), pp.23~36 (2007)
22. Gartel AL, "miRNAs: Little known mediators of oncogenesis", Seminars in Cancer Biology, 18(2), pp.103~110 (2008)
23. Kosik KS, "The neuronal microRNA system", Nature Reviews Neuroscience, 7(12), pp.911~920 (2006)
24. Barbato C, "Searching for MIND : MicroRNAs in neurodegenerative diseases", Journal of Biomedicine and Biotechnology, 2009, pp.871313~ (2009)
25. Fragkouli A., "iR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway", Frontiers in Cellular Neuroscience, 3(8), pp.182~ (2014)
26. Porras G, "Modeling Parkinson’s disease in privates:The MPTP model", Cold Spring Harbor Perspectives in Medicine, 2(3), pp.a009308~ (2012)
27. Jackson-Lewis V., "Protocol for the MPTP mouse model of Parkinson’s disease", Nature Protocols, 2(1), pp.141~151 (2007)
28. Markey SP, "Intraneuronal generation of a pyridinium metabolite may cause druginduced parkinsonism", Nature, 311(5985), pp.464~467 (1984)
29. Nicklas WJ, "Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine", Life Sciences, 36(26), pp.2503~2508 (1985)
30. Maries E, "The role of alpha-synuclein in Parkinson’s disease : insights from animal models", Nature Reviews Neuroscience, 4(9), pp.727~738 (2003)
31. Vila M, "Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP", Journal of Neurochemistry, 74(2), pp.721~729 (2000)
32. Iansek R, "Pharmacological management of Parkinson’s disease", Journal of Pharmacy Practice and Research, 34(30), pp.229~232 (2004)
33. Jankovic J, "Medical management of levodopa-associated motor complications in patients with Parkinson’s disease", CNS Drugs, 21(8), pp.677~692 (2007)
34. Bergen JL, "Aerobic exercise intervention improves aerobic capacity and movement initiation in Parkinson’s disease patients", NeuroRehabilitation, 17(2), pp.161~168 (2002)
35. Picelli A, "Does robotic gait training improve balance in Parkinson’s disease? A randomized controlled trial", Parkinsonism & Related Disorders, 18(8), pp.990~993 (2012)
36. Lau YS, "Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson’s disease with moderate neurodegeneration", European Journal of Neuroscience, 33(7), pp.1264~1274 (2011)
37. Petzinger GM, "Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’’s disease", The Lancet Neurology, 12(7), pp.716~726 (2013)
38. Tuon T, "Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson’s disease", Neuroscience, 227, pp.305~312 (2012)
39. Ahmad SO, "Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and probenecid-treated mice", Neuroscience Letters, 450(2), pp.102~105 (2009)
40. Lau YS, "Parkinson’s Disease", pp.109~115 (2005)
41. Hauser DN, "Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism", Neurobiology of Disease, 51, pp.35~42 (2013)
42. Liu J, "Neuroprotective effects of Jitai tablet, a traditional chinese medicine, on the MPTP-Induced acute model of Parkinson’s disease: involvement of the dopamine system", Evidence-Based Complementary and Alternative Medicine, pp.2014;54238~ (2014)
43. Wang XL, "Gastrodin prevents motor deficits and oxidative stress in the MPTP mouse model of Parkinson’s disease : involvement of ERK1", 2-Nrf2 signaling pathway, 2014, pp.114(2), 77~85
44. Gorton LM, "Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse", Behavioural Brain Research, 213(2), pp.253~262 (2010)
45. Petzinger GM, "Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury", Journal of Neuroscience, 27(20), pp.5291~5300 (2007)
46. Bushati N, "MicroRNA functions", Annual Review of Cell and Developmental Biology, 23, pp.175~205 (2007)
47. Heman-Ackah SM, "RISC in PD : The impact of microRNAs in Parkinson’s disease cellular and molecular pathogenesis", Frontiers in Molecular Neuroscience, 6, pp.40~ (2013)
48. Chen X, "The human NACP", alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis, 1995, pp.26(2), 425~427
49. Maroteaux L, "Synuclein : A neuron-specific protein localized to the nucleus and presynaptic nerve terminal", Journal of Neuroscience, 8(8), pp.2804~2815 (1988)
50. Auluck PK, "α-Synuclein : Membrane interactions and toxicity in Parkinson’s disease", Annual Review of Cell and Developmental Biology, 26, pp.211~233 (2010)
51. Bartels T, "α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation", Nature, 477(7362), pp.107~110 (2011)
52. Yasuda T, "α-Synuclein and neuronal cell death", Molecular Neurobiology, 47(2), pp.466~483 (2013)
53. 백자현, "Dopamine signaling in food addiction: role of dopamine D2 receptors", BMB Reports, 46(11), pp.519~526 (2013), 생화학분자생물학회
54. Tritsch NX, "Dopaminergic modulation of synaptic transmission in cortex and striatum", Neuron, 76(1), pp.33~50 (2012)
55. Blanchard-Fillion B, "Nitration and inactivation of tyrosine hydroxylase by peroxynitrite", The Journal of Biological Chemistry, 276(49), pp.46017~46023 (2001)
56. Tabrez S, "A synopsis on the role of tyrosine hydroxylase in Parkinson’s disease", CNS & Neurological Disorders-Drug Targets, 11(4), pp.395~409 (2012)
57. Gao N, "Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene", Neuroscience Bulletin, 23(1), pp.53~57 (2007)
58. Corti O, "What genetics tells us about the causes and mechanisms of Parkinson’s disease", Physiological Reviews, 91(4), pp.1161~1218 (2011)
59. Cenci MA, "Presynaptic mechanisms of l-DOPA-induced dyskinesia : The findings, the bebate, and the therapeutic implications", Frontiers in Neurology, 15(5), pp.242~ (2014)

관련 논문AI추천